DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing

Dr. Cindy Orser, the Chief Science Officer of DigiPath Labs, the cannabis testing subsidiary of DigiPath, Inc. (DIGP), was recently interviewed by United Patients Group about the lack of consistency in today’s medical cannabis testing industry. In her talk with the online resource for medical cannabis information, she explained that the state-to-state variations in cannabis laws are hurting patients because their lack of uniform requirements makes standardization impossible.

Dr. Orser is actively engaging with State of Nevada officials to help create the nation’s most stringent medical cannabis testing protocols, and she works directly with the Conference of Western Attorneys General (CWAG) to adopt those standards in other cannabis-legal states.

“Standards define how we live. They’re seamlessly incorporated into our life,” Dr. Orser recently told the CWAG members at their annual conference. “When you go get sixteen gallons of high-octane gas, you don’t worry that that’s not what you just put into your tank. You take an aspirin, and it’s 325 mg—you don’t even think about it. We need that kind of reliability in the medical cannabis industry.”

The article points out that, while 23 states and Washington, DC, allow medical cannabis use, only twelve states currently require any kind of cannabis testing so far, and no state sets uniform testing-lab standards for testing, calibration, or exchange of standards between labs.

“Because cannabis remains illegal on the federal level, the FDA is not there to set uniform standards for cannabis safety the way it does for other medicine,” notes DigiPath Labs CEO Todd Denkin. “If we’re going to call it medicine, we have to treat it like medicine and standardized testing and testing protocols is a must.”

Dr. Orser is especially concerned about pesticides in cannabis because they are particularly harmful to patients with compromised immune systems, and they only get stronger in cannabis concentrates.

“Our goal is to weed out cannabis products with unsafe levels of pesticides that can aggravate patient health problems, such as liver disease. It is in the best interest of every entity involved in the cannabis enterprise—from the producer to the dispensary owner to the State—to embrace the most rigorous testing requirements from a liability as well as a consumer and patient safety standpoint,” says Dr. Orser.

Dr. Orser set up DigiPath’s first testing lab, in Las Vegas, with top-of-the-line equipment, exacting SOPs, and mandatory quality-assurance testing. In adopting the standards that Dr. Orser is helping to design, Nevada will become a national model for assuring patient safety.

The attorneys general and lawmakers in other states are beginning to see the need for uniform standards, and Dr. Orser is hopeful that by raising awareness of the lack of cannabis testing requirements, legislation will be created to address this issue.

“It is time to have a national discussion to move toward a more unified approach to cannabis production, safety, and quality assurance testing,” Dr. Orser declares.

For more information about DigiPath Labs, go to http://digipathlabs.com/. For interview requests with Dr. Orser, please email: info@digipath.com or call (702) 209-2429.

About DigiPath, Inc. (DIGP)

DigiPath, Inc., supports the cannabis industry’s best practices for reliable testing and brings unbiased cannabis news coverage, interviews and education to the nation. DigiPath’s three business units are DigiPath Labs, TNM News Corp., and DigiPath Corp.

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements are based on information available at the time they are made, and are subject to risks and uncertainties that could cause actual performance to differ materially from those stated. For a description of the risk factors and uncertainties affecting DigiPath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Thomas Mitchell

Mr. Mitchell has over a decade of experience in the financial markets as both a private investor and financial journalist.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Search CannabisFN

Press Coverage

Psychedelics Index

Top Videos

CFN Media / Paul Rosen

Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]

Sumit Mehta of MAZAKALI

In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures.  A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]

Hemptown USA Inc.

From the rich soils of Southern Oregon, Kentucky and Colorado, Hemptown USA is growing some of the finest high cannabinoid hemp plants in the world.

Gabriella’s Kitchen Inc.

Gabriella’s Kitchen (GABY) is a pure-play cannabis wellness company.

Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer